
Transplantation is the optimal treatment for patients with kidney failure, but rejection still causes premature graft loss in as many as 30 per cent of recipients. This project aims to cut the rejection rate by in half by using genomic technologies to improve the matching of donors and recipients, to monitor the immune response for rejection, and to develop personalized drug treatment regimes for each recipient. It offers the potential for $1 billion in healthcare savings over the next 15 years.
How are we going to positively impact transplant patients?
Tomorrow's Transplants
Transplant medicine is moving toward a future of precision medicine that will improve long-term patient outcomes. How success in transplant is defined in 2018 may look much different from what will define success in 2025.
50 Years of Transplant
October 24, 2018, marks 50 years since the first ever transplant in British Columbia.
Today thousands of British Columbians are alive because of an organ transplant.
Why GCTC?
The world of transplantation is changing at a breathtaking pace. We are committed to building a ground-breaking research team with a drive to translate research findings into clinical action, ultimately leading to continuous improvement for our patients in BC and beyond.
Our hope is to develop answers that holds the key to unleashing innovations across all areas of patient care, from increasing the supply of organs available for transplant, reducing organ rejection, improving immunosuppressive drugs, and monitoring health outcomes for transplant recipients.
Why GCTC?
The world of transplantation is changing at a breathtaking pace. We are committed to building a ground-breaking research team with a drive to translate research findings into clinical action, ultimately leading to continuous improvement for our patients in BC and beyond.
Our hope is to develop answers that holds the key to unleashing innovations across all areas of patient care, from increasing the supply of organs available for transplant, reducing organ rejection, improving immunosuppressive drugs, and monitoring health outcomes for transplant recipients.
Project Highlights
Project Leaders
- Paul Keown (UBC)
- Ruth Sapir-Pichhadze
(McGill University) - Timothy Caulfield (University of Alberta)
- Stirling Bryan (UBC)
Genome Centres
- Genome British Columbia (administrative lead)
- Génome Québec
- Genome Alberta
Total Funding
- $10.8 million
- Total Funding In-kind contribution from private and industrial stakeholders
Join the @GenomeCanadaTx conversation
Twitter feed is not available at the moment.
Latest Articles

Best Poster Winners at BC Kidney Days

The Future of Immunology at VGH: Personalized Medicine in Immune and Inflammatory Diseases

VGH Immunology pioneers NGS HLA typing for Canada: From Serology to Sequencing.

Dr. Keown presents the Future of Precision Medicine in Renal Transplantation
